![]() ![]() Doses of concurrent antidiabetic drugs may require adjustment. New-onset type 2 diabetes mellitus has been reported. Glucose intolerance and diabetes mellitus: Treatment with somatropin may decrease insulin sensitivity, particularly at higher doses.Monitor patients carefully for increased growth, or potential malignant changes, of preexisting nevi. Pediatric patients with certain rare genetic causes of short stature have an increased risk of developing malignancies and should be carefully monitored for development of neoplasms. In childhood cancer survivors who were treated with radiation to the brain/head for their first neoplasm and who developed subsequent GHD and were treated with somatropin, an increased risk of a second neoplasm, in particular meningiomas, has been reported. Increased risk of neoplasms: Monitor patients with preexisting tumors for progression or recurrence.Evaluate patients for signs of upper airway obstruction and sleep apnea before initiation of treatment. Sudden death in pediatric patients with Prader-Willi Syndrome has been reported after initiating treatment with somatropin with one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. ![]() Increased mortality in patients with acute critical illness due to complications following open heart or abdominal surgery or multiple accidental trauma, or those with respiratory failure has been reported.Norditropin ® is also indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD) Important Safety Information Contraindications growth failure due to Prader-Willi syndrome (PWS).Idiopathic Short Stature (ISS), height standard deviation score (SDS) short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4 years of age.short stature associated with Turner syndrome,.short stature associated with Noonan syndrome,.growth failure due to inadequate secretion of endogenous growth hormone (GH).Norditropin ® (somatropin) injection is indicated for the treatment of pediatric patients with: Pediatric patients with closed epiphyses.Active proliferative or severe non-proliferative diabetic retinopathy.Systemic hypersensitivity reactions have been reported with postmarketing use of somatropin products Hypersensitivity to Norditropin ® or any of its excipients.Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment due to the risk of sudden death.Acute critical illness after open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure due to the risk of increased mortality with use of pharmacologic doses of somatropin.Norditropin ® is contraindicated in patients with: Selected Important Safety Information for Norditropin ® Contraindications ![]()
0 Comments
Leave a Reply. |